Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- JANX
- Price
- 15.14
- Stock movement up
- +1.87 (14.09%)
- Company name
- Janux Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 910.64M
- Ent value
- 910.46M
- Price/Sales
- 611.99
- Price/Book
- 0.93
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -62.99%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
JANX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 611.99 |
| Price to Book | 0.93 |
| EV to Sales | 611.87 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 60.15M |
| EPS (TTM) | -1.64 |
| FCF per share (TTM) | -1.15 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.49M |
| Gross profit (TTM) | -1.11M |
| Operating income (TTM) | -144.29M |
| Net income (TTM) | -101.89M |
| EPS (TTM) | -1.64 |
| EPS (1y forward) | -2.98 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -74.66% |
| Operating margin (TTM) | -9696.77% |
| Profit margin (TTM) | -6847.78% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 48.39M |
| Net receivables | 6.32M |
| Total current assets | 998.09M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 29.74M |
| Total assets | 1.02B |
| Accounts payable | 3.40M |
| Short/Current long term debt | 22.66M |
| Total current liabilities | 27.83M |
| Total liabilities | 48.21M |
| Shareholder's equity | 976.55M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -70.42M |
| Capital expenditures (TTM) | 979.00K |
| Free cash flow (TTM) | -71.40M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -10.43% |
| Return on Assets | -9.94% |
| Return on Invested Capital | -10.41% |
| Cash Return on Invested Capital | -7.29% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 13.79 |
| Daily high | 15.28 |
| Daily low | 13.46 |
| Daily Volume | 6.15M |
| All-time high | 66.83 |
| 1y analyst estimate | 65.12 |
| Beta | 2.81 |
| EPS (TTM) | -1.64 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 6 Mar 2026 |
Downside potential
Loading...
Downside potential data
| JANX | S&P500 | |
| Current price drop from All-time high | -77.35% | -0.89% |
| Highest price drop | -80.32% | -19.00% |
| Date of highest drop | 20 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -51.98% | -2.49% |
| Avg time to new high | 322 days | 6 days |
| Max time to new high | 283 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
910.64M
Marketcap category
Small-cap
Description
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Employees
109
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page